Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.
BACKGROUND AND PURPOSE Continuous , hyperfractionated , accelerated radiotherapy ( CHART ) has shown promise of improved tumour control and reduced late morbidity in pilot studies and has now been tested in a multicentre r and omised controlled clinical trial . MATERIAL AND METHODS Patients with squamous cell cancer in the main sites within the head and neck region with the general exception of early T1 N0 tumours were entered into the study by 11 centres . There was a 3:2 r and omisation to either CHART , where a dose of 54 Gy was given in 36 fractions over 12 days , or to conventional therapy where 66 Gy was given in 33 fractions over 6.5 weeks . A total of 918 patients were included over a 5 year period from March 1990 . RESULTS ACUTE MORBIDITY : Acute radiation mucositis was more severe with CHART , occurred earlier but settled sooner and was in nearly all cases healed by 8 weeks in both arms . Skin reactions were less severe and settled more quickly in the CHART treated patients . TUMOUR CONTROL AND SURVIVAL : Life table analyses of loco-regional control , primary tumour control , nodal control , disease-free interval , freedom from metastasis and survival showed no evidence of differences between the two arms . In exploratory subgroup analyses there was evidence of a greater response to  CHART  in younger patients ( P = 0.041 ) and poorly differentiated tumours appeared to fare better with conventional radiotherapy ( P = 0.030 ) . In the larynx there was evidence of a trend towards increasing benefit with more advanced T stage ( P = 0.002 ) . LATE TREATMENT RELATED MORBIDITY : Osteoradionecrosis occurred in 0.4 % of patients after CHART and 1.4 % of patients after conventional radiotherapy . The incidence of chondritis or cartilage necrosis was similar in both arms . Life table analysis showed evidence of reduced severity in a number of late morbidities in favour of CHART . These were most striking for skin telangiectasia , superficial and deep ulceration of the mucosa and laryngeal oedema . CONCLUSION Similar local turnout control was achieved by CHART as compared with conventional radiotherapy despite the reduction in total dose from 66 to 54 Gy supporting the importance of re population as a cause of radiation failure . The effects seen in advanced laryngeal cancer and those related to histological differentiation need further study . Reduced late morbidity is a factor which together with patient preference should be considered in the decision as to the programme of radiotherapy to employ in the curative treatment of head and neck cancer
Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘